Nomura Securities analyst , M. Ian Somaiya reiterated a Buy rating on Intercept Pharmaceuticals (NASDAQ: ICPT) but trimmed his price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE